The Inhibition of Src Family Kinase Suppresses Pancreatic Cancer Cell Proliferation, Migration, and Invasion
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Src is considered a rising therapeutic target for the treatment of solid tumors, and Src family kinases (SFKs) participate in cancer cell proliferation and survival. The role of SFK suppression was investigated in the proliferation, migration, and invasion of pancreatic cancer cells. METHODS: Knockdown of the SFKs in pancreatic cancer cells was achieved by transfecting small interfering RNAs, and its effects were investigated using proliferation, wound, and invasion assays. RESULTS: The SFK inhibitors suppressed proliferation and induced cell cycle arrest in pancreatic cancer cells. The SFK messenger RNA profiles showed that Yes1, Lyn, Fyn, Frk, Hck, and Src were expressed. Specific small interfering RNA transfection suppressed the messenger RNA expressions of Yes1, Lyn, Fyn, Frk, and Src, and the knockdown suppressed cell proliferation by 16.7% to 47.3% in PANC-1 cells. Knockdown of any of these 5 SFKs suppressed proliferation in other pancreatic cancer cell lines by 3.0% to 40.5%. The knockdowns significantly reduced pancreatic cancer cell migration by 24.9% to 66.7% and completely inhibited invasion. CONCLUSIONS: These results suggest that the knockdown of Yes1, Lyn, Fyn, Frk, or Src reduce human pancreatic cancer cell proliferation, migration, and invasion, and that SFKs should be viewed as critical therapeutic targets of pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Src family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis
Bowman, T., Broome, M. A., Sinibaldi, D., Wharton, W., Pledger, W. J., Sedivy, J. M., Irby, R., Yeatman, T., Courtneidge, S. A., & Jove, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131568898 · Cited by 488
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection
Palliser, D., Chowdhury, D., Wang, Q.-Y., Lee, S. J., Bronson, R. T., Knipe, D. M., & Lieberman, J. (2006) · Nature · doi:10.1038/nature04263 · Cited by 410 · cited 1×
“Small interfering RNAs have been used in studies on specific disease conditions in cultured cells and in animals.(41) In humans, the systemic administration of siRNA by direct intravenous administration to patients with solid cancers supports the usefulness of the siRNA approach to knockdown target proteins in cancers.”
BackgroundThe Role of Src in Solid Tumors
Wheeler, D. L., Iida, M., & Dunn, E. F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0009 · Cited by 346 · cited 3×
“Src kinases are known to be overexpressed in various tumors, including colon cancer and breast cancer.(5) The overexpression and activity of Src is regarded to play an important role in cancer progression, malignancy, and prognosis, and several inhibitors targeting Src are under clinical investigation.”
BackgroundDuxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1183-3 · Cited by 192 · cited 1×
“Studies indicate that activated Src is important for pancreatic tumor growth and metastases and suggest that Src is an attractive therapeutic target in pancreatic cancer.(13,27) However, despite emphasis on the therapeutic role of Src inhibition, other SFKmembers have received little attention in the context of pancre…”
BackgroundCurrent status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Cited by
Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
Martellucci, S., Clementi, L., Sabetta, S., Mattei, V., Botta, L., & Angelucci, A. (2020) · Cancers · doi:10.3390/cancers12061448 · Cited by 139
“However, other reports of a potential pro-oncogenic function of Frk also exist, such as in studies evaluating the therapeutic potential of SFKs in liver and pancreatic cancer cell lines [7,8].”
Zhang, L., Yang, Y., Chai, L., Bu, H., Yang, Y., Huang, H., Ran, J., Zhu, Y., Li, L., Chen, F., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32530 · Cited by 29
Plangger, A., Rath, B., Stickler, S., Hochmair, M., Lang, C., Weigl, L., Funovics, M., & Hamilton, G. (2022) · Discover Oncology · doi:10.1007/s12672-022-00550-w · Cited by 25
“Furthermore, regulation of KRAS occurs by phosphorylation of tyrosine residues by members of the Src family of tyrosine kinases (SFKs), three of which, Src, Fyn, and Yes, are expressed in pancreatic cancer cell lines [86].”
Background
Metadata
- Authors
- Je, D. W., O, Y. M., Ji, Y. G., Cho, Y., & Lee, D. H.
- Venue
- Pancreas
- Published
- 2014-07
- Volume
- 43
- Issue
- 5
- Pages
- 768-776
- ISSN
- 0885-3177 (ISSN-L)
- OpenAlex
- W2060312656
- Cited by
- 71
- References
- 6
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Inhibition of Src Family Kinase Suppresses Pancreatic Cancer Cell Proliferation, Migration, and Invasion. https://app.cochat.ai/papers/10.1097/mpa.0000000000000103
- The paper
- Je, D. W., O, Y. M., Ji, Y. G., Cho, Y., & Lee, D. H. (2014). The Inhibition of Src Family Kinase Suppresses Pancreatic Cancer Cell Proliferation, Migration, and Invasion. Pancreas. https://doi.org/10.1097/mpa.0000000000000103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.